Session 3 : Therapeutic Applications II

To date, the most difficult challenge to antibodybased therapy for a variety of diseases, particularly for cancer, is the balance of robust efficacy and minimal side effects on normal tissues. In the case of cancer intervention, it is highly desirable to have a therapeutics controlling metastasis that accounts for most death of cancer patients and enhancing antitumor immunity that is seriously weakened in patients with cancer. Antibody-directed therapeutics has been primarily focused on targeting a specific molecule that is functional in the pathogenesis of diseases. Antibody combination and bispecific antibody targeting disorder-associated cells or factors have been explored in the past years. Alternatively, the development of a therapeutic antibody targeting multiple molecules that involve in the pathogenesis and progression of one or more disease types will be also preferable.